ClinicalTrials.gg
CompletedNCT00082433Updated Nov 2, 2020Results posted

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

A Phase 3 interventional study of Ixabepilone + Capecitabine and Capecitabine in Cancer and Breast Cancer, sponsored by R-Pharm. Completed at 189 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.

Primary conditionBreast NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. The study's listed conditions name Breast Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by R-Pharm · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,221
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.

Enrollment
Largest of 39
1,221 · median 56
Started
2003
with 1 other
Phase 3
5 of 41
none open now
Registered
8th of 41
by date
Lead sponsor
13 of 41
R-Pharm

Among the 41 studies testing ixabepilone in Breast Neoplasms, this one has the largest enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2003, is one of 5 in phase 3, and was the 8th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About ixabepilone

ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing ixabepilone in Breast Neoplasms as a file.
02

Study summary

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.

03

Conditions studied

  • Cancer
  • Breast Cancer

Browse trials for

04

In context

Breast Neoplasms Reclassified

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's enrollment of 1,221 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  • Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
  • Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for disease must have within one year.
  • Patients may not have any history of brain and/or .
  • Patients may not have Grade 2 or worse neuropathy at the time of study entry.
  • Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,221 participants (actual)

Study arms

  • Experimental
    A

    Drug: Ixabepilone + Capecitabine

  • Active comparator
    B

    Drug: Capecitabine

Interventions

  • DrugIxabepilone + Capecitabine

    Drug pages: Ixabepilone · Capecitabine

    Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle

    Also known as: IXEMPRA®, Epothilone

  • Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.

    Time frame: from date of randomization until death

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.

    Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression

  2. Response Rate (RR)

    RR=number of patients in that group whose best response is "partial"(30% decrease in the sum of the longest diameter of target lesions) or "complete" (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants

    Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression

  3. Duration of Response

    Measured from the time RECIST criteria (described in previous outcome measure) were first met for "complete" or "partial" response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.

    Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression

  4. Time to Response

    Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for "partial" or "complete" (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).

    Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression

  5. Treatment-Related Safety Summary

    Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0

    Time frame: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.

  6. Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)

    Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.

    Time frame: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment

08

Results

Posted Aug 17, 2009

Participant flow

Participant flow — Overall Study
MilestoneIxabepilone + CapecitabineCapecitabine
Started609612
Completed1515
Not completed594597
Withdrew: Adverse event1217
Withdrew: Death818
Withdrew: Disease progression/relapse270388
Withdrew: Physician decision5061
Withdrew: Lost to follow-up12
Withdrew: Study drug toxicity17966
Withdrew: Withdrawal by subject5530
Withdrew: Still on treatment21
Withdrew: Not treated1211
Withdrew: Ineligible21
Withdrew: Noncompliance21
Withdrew: New primary cancer10
Withdrew: Impending surgery01

Outcome measures

SecondaryProgression-Free Survival (PFS)

PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.

Time frame:
every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIxabepilone + CapecitabineCapecitabine
Progression-Free Survival (PFS)6.24 (5.59 to 6.77)4.40 (4.14 to 5.42)
Statistical analysis
  • Ixabepilone + Capecitabine vs Capecitabine · Log Rank · p = .0005 · Hazard ratio (hr): .79 · 95% CI .69 to .90
SecondaryResponse Rate (RR)

RR=number of patients in that group whose best response is "partial"(30% decrease in the sum of the longest diameter of target lesions) or "complete" (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants

Time frame:
every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Reported as:
Mean · percentage of participants
Response Rate (RR)
percentage of participantsIxabepilone + CapecitabineCapecitabine
Response Rate (RR)43.3 (38.7 to 47.9)28.8 (24.7 to 33.2)
Statistical analysis
  • Ixabepilone + Capecitabine vs Capecitabine · Cochran-Mantel-Haenszel · p = <.0001 · Odds ratio (or): 1.89 · 95% CI 1.44 to 2.50
SecondaryDuration of Response

Measured from the time RECIST criteria (described in previous outcome measure) were first met for "complete" or "partial" response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.

Time frame:
every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Reported as:
Median · Months
Duration of Response
MonthsIxabepilone + CapecitabineCapecitabine
Duration of Response6.1 (5.5 to 7.0)6.3 (5.3 to 7.6)
SecondaryTime to Response

Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for "partial" or "complete" (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).

Time frame:
every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Reported as:
Median · weeks
Time to Response
weeksIxabepilone + CapecitabineCapecitabine
Time to Response6.6 (4.7 to 47.9)6.6 (4.6 to 59.4)
SecondaryTreatment-Related Safety Summary

Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0

Time frame:
safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.
Reported as:
Number · Participants
Treatment-Related Safety Summary
ParticipantsIxabepilone + CapecitabineCapecitabine
Deaths within 30 days of last dose1942
Treatment-related serious adverse events12564
Treatment-related Grade 3-4 adverse events458240
Treatment-related AEs leading to discontinuation28666
SecondarySymptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)

Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.

Time frame:
Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment
Reported as:
Mean · units on a scale
Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
units on a scaleIxabepilone + CapecitabineCapecitabine
Week 3 (n=440; n=429)-0.5 ± 13.70.0 ± 4.7
Week 6 (n=379; n=353)-0.9 ± 15.40.5 ± 5.0
Week 9 (n=330; n=283)-1.5 ± 17.40.7 ± 5.0
Week 12 (n=283; n=250)-1.4 ± 17.31.1 ± 5.2
Week 15 (n=255; n=240)-1.9 ± 17.01.5 ± 5.0
Week 18 (n=205; n=202)-1.3 ± 15.71.2 ± 5.4
Week 21 (n=166; n=185)-1.4 ± 16.81.7 ± 5.1
Week 24 (n=149; n=141)-1.4 ± 17.31.1 ± 5.4
Statistical analysis
  • Ixabepilone + Capecitabine vs Capecitabine · Wei-Lachin · p = <0.0001
PrimaryOverall Survival (OS)

Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.

Time frame:
from date of randomization until death
Reported as:
Median · months
Overall Survival (OS)
monthsIxabepilone + CapecitabineCapecitabine
Overall Survival (OS)16.39 (14.95 to 17.91)15.64 (13.86 to 17.02)
Statistical analysis
  • Ixabepilone + Capecitabine vs Capecitabine · Log Rank · p = .1162 (The test was stratified by (taxane resistance \[yes/no\], measurable disease versus non-measurable disease, prior chemotherapy for metastatic disease \[yes/no\], and anthracycline resistance \[yes/no\]).) · Hazard ratio (hr): .90 · 95% CI .78 to 1.03The analysis was conducted at the 0.05 level and no adjustments were performed
  • Ixabepilone + Capecitabine vs Capecitabine · Regression, Cox · p = .0231 · Hazard ratio (hr): .85 · 95% CI .75 to .98

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine—192/603 (31.8%)564/603 (93.5%)
Ixabepilone + Capecitabine—205/595 (34.5%)590/595 (99.2%)
Most frequent serious events
Showing 10 of 233
Most frequent serious events
EventCapecitabineIxabepilone + Capecitabine
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)43/60317/595
FEBRILE NEUTROPENIABlood and lymphatic system disorders5/60334/595
DIARRHOEAGastrointestinal disorders33/60323/595
DYSPNOEARespiratory, thoracic and mediastinal disorders25/60310/595
VOMITINGGastrointestinal disorders17/60324/595
NEUTROPENIABlood and lymphatic system disorders8/60318/595
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders13/6037/595
NAUSEAGastrointestinal disorders7/60312/595
MALIGNANT PLEURAL EFFUSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/6035/595
LEUKOPENIABlood and lymphatic system disorders1/6038/595
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCapecitabineIxabepilone + Capecitabine
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders412/603383/595
NAUSEAGastrointestinal disorders243/603315/595
FATIGUEGeneral disorders166/603272/595
DIARRHOEAGastrointestinal disorders244/603266/595
PERIPHERAL SENSORY NEUROPATHYNervous system disorders64/603258/595
VOMITINGGastrointestinal disorders168/603250/595
ALOPECIASkin and subcutaneous tissue disorders20/603245/595
WEIGHT DECREASEDInvestigations104/603194/595
NAIL DISORDERSkin and subcutaneous tissue disorders77/603193/595
ANOREXIAMetabolism and nutrition disorders99/603183/595

Baseline characteristics

Age, Customized
Age, Customized(participants)Ixabepilone + CapecitabineCapecitabineTotal
<65 years5325311063
≥65 years7781158
<50 years225235460
≥50 years384377761
Age, Continuous
Age, Continuous(years)Ixabepilone + CapecitabineCapecitabineTotal
Median53.0 (23.0 to 78.0)53.0 (24.0 to 81.0)53.0 (23.0 to 81.0)
Sex: Female, Male
Sex: Female, Male(Participants)Ixabepilone + CapecitabineCapecitabineTotal
Female6096121221
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ixabepilone + CapecitabineCapecitabineTotal
American Indian or Alaska Native123
Asian9069159
Black or African American252146
White480502982
Unknown or Not Reported131831
Karnofsky performance Status
Karnofsky performance Status(units on a scale)Ixabepilone + CapecitabineCapecitabineTotal
100219265484
90187188375
80151130281
70442670
<70224
not reported617
Menopausal Status
Menopausal Status(participants)Ixabepilone + CapecitabineCapecitabineTotal
Premenopausal9390183
Perimenopausal323264
Postmenopausal475481956
Not Reported9918
Organ Sites
Organ Sites(participants)Ixabepilone + CapecitabineCapecitabineTotal
Ascites131629
Bone283287570
Brain011
Breast415495
Chest Wall Mass473885
CNS101
Cutaneous6457121
Effusion7714
Intestine112
Lymph Node236233469
Mediastinum5452106
Other173047
Pleura8684170
Subcutaneous232447
Visceral, Liver273276549
Visceral, Lung221217438
Visceral, Other242650
Presence with at least 1 lesion
Presence with at least 1 lesion(participants)Ixabepilone + CapecitabineCapecitabineTotal
Number6066121218
09

Study locations

189 sites
  • Local Institution
    Tucson, Arizona, United States
  • Local Institution
    Beverly Hills, California, United States
  • Local Institution
    Corona, California, United States
  • Local Institution
    Hartford, Connecticut, United States
  • Local Institution
    Plantation, Florida, United States
  • Local Institution
    Boise, Idaho, United States
  • Local Institution
    Evanston, Illinois, United States
  • Local Institution
    Iowa City, Iowa, United States
  • Local Institution
    Louisville, Kentucky, United States
  • Local Institution
    Baton Rouge, Louisiana, United States
  • Local Institution
    Bethesda, Maryland, United States
  • Local Institution
    Boston, Massachusetts, United States
  • Local Institution
    Jackson, Mississippi, United States
  • Local Institution
    Columbia, Missouri, United States
  • Local Institution
    Voorhees, New Jersey, United States
  • Local Institution
    Albuquerque, New Mexico, United States
  • Local Institution
    Bronx, New York, United States
  • Local Institution
    Latham, New York, United States
  • Local Institution
    Mineola, New York, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Durham, North Carolina, United States
  • Local Institution
    Goldsboro, North Carolina, United States
  • Local Institution
    Hickory, North Carolina, United States
  • Local Institution
    Kinston, North Carolina, United States
  • Local Institution
    Canton, Ohio, United States
  • Local Institution
    Columbus, Ohio, United States
  • Local Institution
    Langhorne, Pennsylvania, United States
  • Local Institution
    Knoxville, Tennessee, United States
  • Local Institution
    Memphis, Tennessee, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Charlottesville, Virginia, United States
  • Local Institution
    Norfolk, Virginia, United States
  • Local Institution
    Richmond, Virginia, United States
  • Local Institution
    Marshfield, Wisconsin, United States
  • Local Institution
    Avelianeda, Buenos Aires, Argentina
  • Local Institution
    Bahia Blanca, Buenos Aires, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
  • Local Institution
    Escobar, Buenos Aires, Argentina
  • Local Institution
    Resistencia, Chaco, Argentina
  • Local Institution
    Barrio Alto Verde, Cordoba, Argentina
  • Local Institution
    San Miguel De Tucuman, Tucuman, Argentina
  • Local Institution
    Buenos Aires, Argentina
  • Local Institution
    Mendoza, Argentina
  • Local Institution
    Salta, Argentina
  • Local Institution
    Santa Fe, Argentina
  • Local Institution
    Sydney, New South Wales, Australia
  • Local Institution
    Westmead, New South Wales, Australia
  • Local Institution
    Brisbane, Queensland, Australia
  • Local Institution
    Herston, Queensland, Australia
  • Local Institution
    South Brisbane, Queensland, Australia
  • Local Institution
    Toowoomba, Queensland, Australia
  • Local Institution
    Adelaide, South Australia, Australia
  • Local Institution
    Woodville, South Australia, Australia
  • Local Institution
    East Melbourne, Victoria, Australia
  • Local Institution
    Parkville, Victoria, Australia
  • Local Institution
    Perth, Western Australia, Australia
  • Local Institution
    Graz, Austria
  • Local Institution
    Voecklabruck, Austria
  • Local Institution
    Wien, Austria
  • Local Institution
    Bruxelles, Belgium
  • Local Institution
    Charleroi, Belgium
  • Local Institution
    Gent, Belgium
  • Local Institution
    Hasselt, Belgium
  • Local Institution
    Kortrijk, Belgium
  • Local Institution
    Wilrijk, Belgium
  • Local Institution
    Centro-Porto Alegre, Rio Grande Do Sul, Brazil
  • Local Institution
    Bela Vista, Sao Paulo, Brazil
  • Local Institution
    Higienopolis, Sao Paulo, Brazil
  • Local Institution
    Sao Paulo, Sp, Brazil
  • Local Institution
    Rio De Janeiro, Brazil
  • Local Institution
    Thunder Bay, Ontario, Canada
  • Local Institution
    Montreal, Quebec, Canada
  • Local Institution
    Santiago, Metropolitana, Chile
  • Local Institution
    Beijing, Beijing, China
  • Local Institution
    Guangzhou, Guangdong, China
  • Local Institution
    Nanjing, Jiangsu, China
  • Local Institution
    Dalian, Liaoning, China
  • Local Institution
    Dilian, Liaoning, China
  • Local Institution
    Jinan, Shandong, China
  • Local Institution
    Shanghai, Shanghai, China
  • Local Institution
    Xi'An, Shanxi, China
  • Local Institution
    Hangzhou, Zhejiang, China
  • Local Institution
    Split, Croatia
  • Local Institution
    Zagreb, Croatia
  • Local Institution
    Brno, Czechia
  • Local Institution
    Hradec Kralove, Czechia
  • Local Institution
    Prague 5, Czechia
  • Local Institution
    Prague, Czechia
  • Local Institution
    Aalborg, Denmark
  • Local Institution
    Herlev, Denmark
  • Local Institution
    Kobenhavn O, Denmark
  • Local Institution
    Angers, France
  • Local Institution
    Bordeaux, France
  • Local Institution
    Caen, France
  • Local Institution
    Clermont-Ferrand, France
  • Local Institution
    Colmar, France
  • Local Institution
    Le Mans, France
  • Local Institution
    Metz, France
  • Local Institution
    Paris Cedex 13, France
  • Local Institution
    Pierre Benite, France

Showing the first 100 of 189 sites across 29 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9. PubMed 29522361 ↗
  • Vahdat LT, Vrdoljak E, Gomez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Geriatr Oncol. 2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006. Epub 2013 Aug 23. PubMed 24472478 ↗
  • Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, Vahdat L. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast. 2012 Feb;21(1):89-94. doi: 10.1016/j.breast.2011.09.003. Epub 2011 Sep 21. PubMed 21937232 ↗
  • Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011 Feb;125(3):755-65. doi: 10.1007/s10549-010-1251-y. Epub 2010 Dec 3. PubMed 21128114 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2004
First posted
May 11, 2004
Start
Nov 2003
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Aug 17, 2009
Last update
Nov 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00082433
Lead sponsor
R-Pharm
First posted
May 11, 2004
Start date
Nov 2003
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Aug 17, 2009
Last update
Nov 2, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixabepilone · Capecitabine

Start the discussion